Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Generics Drugs

1594

Prescription generic pharmaceuticals are the non-patented chemical and therapeutic equivalents of brand name innovative drugs. These low-cost alternatives to brand-name products or generic drugs must contain the same active chemical ingredient and rate of absorption as the branded product. The chemical ingredients, along with inert substances, which aid in the body's absorption and in binding the drug, make up the composition of the drug.

The Federal Drug Administration (FDA) does not allow a generic firm to duplicate exactly the brand name formula. The generic manufacturer must alter the ingredients slightly. This is accomplished by adding inert substances, substances that are inactive, to the generic alternative. Inert substances may function as disintegrates, binders, fillers, drying agents, lubricants, coatings, wetting agents, flavorings, coloring, or drying agents. Generic drugs are often up to 50 to 80 percent cheaper than their brand name counterpart and are gaining in popularity among cost-conscious consumers and their third-party payers.

Generic drugs enter into the retail prescription industry in a two-step process. The exclusive patent protection for the brand name product must expire. As a brand name product nears patent expiration, generic competitors apply for approval to the FDA using an Abbreviated New Drug Application (ANDA). Duplicating studies of the original brand name drug is no longer required by the FDA, and many generic companies contract with specialty laboratories to conduct the bioequivalency studies regarding absorption rates. Although the majority of products must meet bioequivalence standards, bronchodilators and topical drugs cannot be measured by absorption rates and are exempt. Injectables do not require biostudies, and oral liquids are reviewed on an individual basis. The drug must receive FDA approval following this rigid testing. The FDA also conducts periodic plant site inspections and surveillance of quality control procedures.

RSS Feeds

All reports in Generics Drugs

< prev 1  2  3  4  5  6  7  8  9  10  next >
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
... Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion”, which provides insights into the cytotoxic therapies market until 2017 for eight oncology indications. The ...  |  more...
$3,500.00
Canada Pharmaceutical Industry
4/1/2012 | published by: Aruvian's R'search
... and Spain and has shown a steady growth trend. The Canadian pharmaceutical industry is gradually becoming more favorable towards generic drugs rather than branded drugs. Pfizer is Canada's leading pharmaceutical company and generic manufacturer Apotex ...  |  more...
$325.00
Top 194 Generic Pharmaceuticals (Global)
4/1/2012 | published by: Plimsoll Publishing Ltd.
... to industry averages.Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation. The following are some of the key findings of this new report: 39 of ...  |  more...
$1,500.00
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies
4/1/2012 | published by: GBI Research
... Technologies finds that the global herpes market is an attractive one, and is expected to witness growth during the forecast period and to provide good opportunities for investors. The expected high growth is attributed to ...  |  more...
$3,500.00
Generic And Innovative Drugs Market In Central Europe 2012
4/1/2012 | published by: PMR Ltd.
... 2012-2014 details the current market structures, policies and procedures for reimbursement in Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria. This timely report features complete information on new legislative developments occurring in each country ...  |  more...
$3,500.00
Prefilled Syringes to 2016
4/1/2012 | published by: Greystone Research Associates
... commercially.  For Fill-and-Finish contractors, market proximity is an important competitive factor, and the past twelve months has seen major prefilled syringe CMOs expanding their operations in regional markets, particularly in North America. This report analyzes ...  |  more...
$3,850.00
Tensions Rising between Branded Drugmakers and Health Plans
3/31/2012 | published by: GlobalData
... Large pharmaceutical companies are in the midst of a wave of patent expirations that is threatening their profitability. As drugmakers face numerous impending patent expirations, they are exploring new options to squeeze revenue out of ...  |  more...
$500.00
Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022
3/26/2012 | published by: Visiongain
... 2012 to 2022. See how companies worldwide are performing and where they are heading. There, you find analytical profiles for leading producers - activities, outlooks and prospects: Teva Pharmaceutical Industries Sandoz Mylan Actavis Hospira Watson ...  |  more...
$2,642.00
Pharmaceuticals – Philippines – a snapshot (2011)
3/16/2012 | published by: Mintel - Snapshots
... hospitals, care homes and surgeries. Market value is at prices available to the consumer. Market size for Pharmaceuticals in Philippines is given in PHP with a minimum of five years' historical data. Market Forecast is ...  |  more...
$600.00
Generic Pharmaceutical Manufacturing in the US - Industry Market Research Report
3/16/2012 | published by: IBISWorld
... the short term. Furthermore, healthcare reform will benefit the industry, with more consumers gaining insurance coverage for prescription drugs, improved generic drug approval processes and an established pathway to approval for biosimilars. As in the ...  |  more...
$910.00
The World Generic Market Report 2012
3/8/2012 | published by: Espicom Healthcare Intelligence
Generics, Pharmaceuticals, Healthcare  |  more...
$1,390.00
The US Pharmaceutical Market Outlook to 2016 - Evolving Opportunities in the Biologics Segment
3/1/2012 | published by: AM Mindpower Solutions
... as market size of the pharmaceutical industry, market segmentation by Branded and Generic drugs, and Prescribed and OTC drugs and Biologics and specialty drugs segments. The report also provides information on the government regulations, export ...  |  more...
$850.00
Pharmaceuticals in Turkey: ISIC 2423
3/1/2012 | published by: Euromonitor International
... the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new ...  |  more...
$600.00
Pharmaceuticals in Indonesia: ISIC 2423
3/1/2012 | published by: Euromonitor International
... the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new ...  |  more...
$600.00
Emerging Pharmaceutical Market - Czech Republic - Planned Healthcare Reform Plans Forecast to Slow Growth Rates
2/29/2012 | published by: GBI Research
... Growth Rates” provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in the Czech Republic. The report analyzes overall pharmaceutical and outsourcing market structure in the Czech Republic. The report provides competitive ...  |  more...
$3,500.00
The Pharmaceutical Market: Slovenia (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: UK (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: Philippines (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: Mexico (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: Egypt (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: Czech Republic (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Outlook for Pharmaceuticals in Central Asia (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... markets of Central Asia contrast well; China and India are two of the largest pharmaceutical markets with very large economies, whilst Bangladesh and Pakistan are two of the smallest pharmaceutical markets with significantly smaller economies.  |  more...
$3,630.00
The Pharmaceutical Market: Turkey (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: Portugal (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
The Pharmaceutical Market: Peru (pdf/xls)
2/17/2012 | published by: Espicom Healthcare Intelligence
... for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators. Specialised intelligence on OTCs, generics, biologics and biosimilars. Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the ...  |  more...
$1,085.00
< prev 1  2  3  4  5  6  7  8  9  10  next >